Pharma Generics Theme  ·  Active Funds Only

Pharma Generics — Mutual Fund Holdings Tracker

Track how many active mutual funds hold pharma generics stocks in India. Monthly data shows where institutional conviction across Sun Pharma, Cipla, Dr Reddys, Lupin, Torrent, Aurobindo, Alkem, Zydus, Mankind and others is rising or falling.

📅 Updated Aug 2026  ·  Index funds and ETFs excluded

43
Stocks Tracked
417
Active Funds Holding (Aug 2026)
₹170,350 Cr
Active MF Investment (Aug 2026)
May 2026 — fund count in May 2026 (base month) · Jun % / Jul % / Aug % — month-on-month change in funds holding the stock · Aug 2026 Funds — funds holding as of Aug 2026 · Overall % — total change May 2026 to Aug 2026. Blue = growing interest, Red = exiting · AUM (₹ Cr) — total market value held by active funds in Aug 2026 Active equity funds only  ·  Index funds and ETFs excluded
# Stock Name May Jun % Jul % Aug % Aug 2026 Funds Overall % AUM (₹ Cr)
1 Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology 219 -1.8%0% -7.9% 198 -9.6% 27,372
2 Torrent Pharmaceuticals LimitedPharmaceuticals & Biotechnology 97 -1%+46.9% +1.4% 143 +47.4% 11,680
3 Mankind Pharma LimitedPharmaceuticals & Biotechnology 103 +3.9%-3.7% -7.8% 95 -7.8% 9,682
4 Cipla LimitedPharmaceuticals & Biotechnology 93 +3.2%-1% -1.1% 94 +1.1% 14,899
5 Aurobindo Pharma LimitedPharmaceuticals & Biotechnology 95 -3.2%-4.3% -3.4% 85 -10.5% 13,400
6 Ajanta Pharma LimitedPharmaceuticals & Biotechnology 81 +7.4%-4.6% -6% 78 -3.7% 7,197
7 Lupin LimitedPharmaceuticals & Biotechnology 100 0%-13% -19.5% 70 -30% 10,407
8 Biocon LimitedPharmaceuticals & Biotechnology 60 +8.3%+20% -11.5% 69 +15% 9,717
9 Dr. Reddy's Laboratories LimitedPharmaceuticals & Biotechnology 65 +3.1%-13.4% +8.6% 63 -3.1% 5,163
10 IPCA Laboratories LimitedPharmaceuticals & Biotechnology 70 +5.7%-8.1% -7.4% 63 -10% 13,953
11 Glenmark Pharmaceuticals LimitedPharmaceuticals & Biotechnology 71 -4.2%-8.8% -1.6% 61 -14.1% 7,069
12 Abbott India LimitedPharmaceuticals & Biotechnology 67 -9%-3.3% -1.7% 58 -13.4% 3,541
13 Alkem Laboratories LimitedPharmaceuticals & Biotechnology 55 +18.2%-4.6% -14.5% 53 -3.6% 7,633
14 Zydus Lifesciences LimitedPharmaceuticals & Biotechnology 31 +12.9%0% +37.1% 48 +54.8% 5,481
15 GlaxoSmithKline Pharmaceuticals LimitedPharmaceuticals & Biotechnology 38 +7.9%-4.9% +7.7% 42 +10.5% 2,735
16 Pfizer LimitedPharmaceuticals & Biotechnology 33 -6.1%-3.2% +6.7% 32 -3% 2,603
17 Eris Lifesciences LimitedPharmaceuticals & Biotechnology 33 0%-3% -12.5% 28 -15.2% 2,429
18 SANOFI CONSUMER HEALTHCAREPharmaceuticals & Biotechnology 33 -9.1%-16.7% -4% 24 -27.3% 1,119
19 Emcure Pharmaceuticals LimitedPharmaceuticals & Biotechnology 21 +19%-16% +4.8% 22 +4.8% 2,383
20 Sudeep Pharma LimitedPharmaceuticals & Biotechnology 19 -15.8%+25% +10% 22 +15.8% 879
21 Corona Remedies LimitedPharmaceuticals & Biotechnology 24 +12.5%-14.8% -8.7% 21 -12.5% 1,420
22 Orchid Pharma LimitedPharmaceuticals & Biotechnology 24 -4.2%-4.3% -4.5% 21 -12.5% 884
23 AstraZeneca Pharma India LimitedPharmaceuticals & Biotechnology 21 0%-4.8% 0% 20 -4.8% 1,037
24 Granules India LimitedPharmaceuticals & Biotechnology 8 +50%-25% +77.8% 16 +100% 517
25 Wockhardt LimitedPharmaceuticals & Biotechnology 25 +8%-11.1% -33.3% 16 -36% 1,293
26 Senores Pharmaceuticals LtdPharmaceuticals & Biotechnology 12 +16.7%+7.1% 0% 15 +25% 433
27 Alembic Pharmaceuticals LimitedPharmaceuticals & Biotechnology 19 -10.5%-5.9% -12.5% 14 -26.3% 1,056
28 Natco Pharma LimitedPharmaceuticals & Biotechnology 15 -13.3%0% +7.7% 14 -6.7% 190
29 Sanofi India LimitedPharmaceuticals & Biotechnology 17 0%-11.8% -13.3% 13 -23.5% 624
30 Marksans Pharma LimitedPharmaceuticals & Biotechnology 10 +10%0% 0% 11 +10% 519
31 Alivus Life SciencesPharmaceuticals & Biotechnology 8 0%-12.5% 0% 7 -12.5% 661
32 FDC LimitedPharmaceuticals & Biotechnology 7 0%0% 0% 7 0% 290
33 Gufic Biosciences Ltd.Pharmaceuticals & Biotechnology 8 -12.5%-28.6% +20% 6 -25% 112
34 Strides Pharma Science LimitedPharmaceuticals & Biotechnology 8 0%-12.5% -14.3% 6 -25% 908
35 Indoco Remedies LtdPharmaceuticals & Biotechnology 8 -25%0% -16.7% 5 -37.5% 326
36 Caplin Point Laboratories LimitedPharmaceuticals & Biotechnology 6 0%-16.7% -20% 4 -33.3% 256
37 Amrutanjan Health Care Ltd.Pharmaceuticals & Biotechnology 2 0%+50% 0% 3 +50% 38
38 Novartis India LimitedPharmaceuticals & Biotechnology 4 0%0% -25% 3 -25% 24
39 Aarti Pharmalabs LimitedPharmaceuticals & Biotechnology 3 0%-33.3% 0% 2 -33.3% 18
40 Unichem Laboratories Ltd.Pharmaceuticals & Biotechnology 2 0%0% 0% 2 0% 339
41 Amanta Healthcare LimitedPharmaceuticals & Biotechnology 1 0%0% 0% 1 0% 38
42 Bajaj Healthcare LimitedPharmaceuticals & Biotechnology 1 0%0% 0% 1 0% 19
43 ZIM LABORATORIES LTDPharmaceuticals & Biotechnology 0% 0% 1 8
44 Bliss GVS Pharma LimitedPharmaceuticals & Biotechnology 1 0%0% -100% -100%
45 JB Chemicals & Pharmaceuticals LimitedPharmaceuticals & Biotechnology 84 -4.8%-100% -100%
46 Zota Health Care LimitedPharmaceuticals & Biotechnology 2 0%-50% -100% -100%
Share:

What are pharma generics stocks and which ones do mutual funds track in India?

Pharma generics stocks include Indian companies that manufacture and sell branded generic formulations in domestic and export markets. The segment covers large-cap leaders like Sun Pharmaceutical, Cipla, Dr Reddys Laboratories, Lupin, Torrent Pharmaceuticals and Aurobindo Pharma, mid-cap names like Alkem Laboratories, Zydus Lifesciences, Mankind Pharma, IPCA Laboratories and Ajanta Pharma, and challenger brands like Glenmark, JB Chemicals, Emcure and Eris Lifesciences. India is the pharmacy of the world — the largest supplier of generic medicines globally by volume — and this theme captures the companies that drive that position.

Rising fund counts over four months signal growing institutional conviction in the pharma generics theme. Cross-reference individual fund portfolios on our top stocks page or explore full holdings via the funds directory.

Why are mutual funds buying pharma generics stocks in India right now?

India pharma generics companies are benefiting from multiple tailwinds simultaneously. US generics pricing has stabilised after years of erosion, improving export margins for companies like Sun Pharma, Lupin and Dr Reddys. Domestic branded generics are growing steadily as healthcare spending rises and insurance coverage expands. Chronic disease categories — cardiovascular, diabetes, oncology — are growing fast and favour companies with strong chronic portfolios like Torrent and Alkem. New product launches, biosimilars, and complex generics are creating incremental growth opportunities. Fund managers hold generics as core defensive positions with export diversification.

For context on SEBI disclosure requirements, refer to AMFI India. For regulatory guidelines, visit SEBI India. Explore broader holding trends using our market cap categories page.

What does the AUM column show on pharma generics theme pages?

The AUM column shows the total market value of holdings in that stock across all active equity mutual funds in the latest month, expressed in crores of rupees. A high AUM alongside a rising fund count signals strong and growing conviction, while a falling fund count with still-high AUM may indicate remaining funds are holding larger positions even as others exit. This data is updated automatically each month as new portfolio disclosures are uploaded.

To explore individual fund portfolios and see which specific funds hold each pharma generics stock, visit the funds directory or click any stock name in the table above. Use the SIP calculator to plan investments in funds with high pharma sector exposure. For a broader market view, see our AAUM data page.

Disclaimer: RightAdvise is a data and research platform. Fund holding data is sourced from monthly portfolio disclosures published by mutual funds as required by SEBI. AUM figures are calculated from reported market values and may differ from official AMC disclosures. This page is for informational purposes only and does not constitute investment advice. Past holding trends do not guarantee future performance. Please consult a SEBI-registered investment adviser before making any investment decisions.